Healthtech Series B Investors & VC Firms
1216 firms in this list, with a median first check of $750K. 285 of them lead rounds. Generated from verified public data and updated continuously.
Goodwater Capital
BurlingamePre-Seed–Late Stage$5M – $50M
10 people
Iter Investments
South FloridaSeed–Series B
15 people
Korelya Capital
ParisSeed–Series C
21 people
PACE Healthcare Capital
ChicagoSeed–Series B$1M – $4M
17 people
Better Ventures Central Llc
OaklandPre-Seed–Growth$500K – $1.5M
4 people
big_bets
Pre-Seed–Series B$300K – $2M
10 people
Solas BioVentures
ChattanoogaPre-Seed–Series B
14 people
Tenmile
Seed–Growth
11 people
MaRS
TorontoPre-Seed–Late Stage
19 people
Athera Venture Partners
BangalorePre-Seed–Growth$480K – $3M
9 people
Informed Ventures Advisors, Llc
Menlo ParkPre-Seed–Late Stage
8 people
Mount Judi Ventures
BengaluruPre-Seed–Series B
18 people
Allumia Ventures
SeattleSeries A–Late Stage$5M – $15M
11 people
11.2 Capital
San FranciscoPre-Seed–Series B$500K – $3M
4 people
IW Capital
LondonSeed–Growth
16 people
MK Capital
NorthfieldSeed–Late Stage$2M – $10M
7 people
Scientia Ventures
New YorkSeries A–Series B
13 people
Yabeo
PullachSeed–Late Stage
13 people
Ascendo Ventures
SeoulPre-Seed–Late Stage
9 people
Delos Capital
CambridgeSeed–Late Stage
12 people
Prime Partners
TokyoPre-Seed–Growth
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$500K – $3M
19 people
Vensana Capital
MinneapolisSeries A–Late Stage
13 people
Quantonation
ParisPre-Seed–Series B
9 people
Related lists
Series B Investors & VC Firms (4094)Healthtech Investors & VC Firms (3208)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Series B Investors & VC Firms in United States (1625)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)
Data sourced from public filings and firms' own websites — see our methodology.










































































